Sirdupla: new LABA/corticosteroid inhaler

Sirdupla (salmeterol/fluticasone) has been launched for use in adults with asthma where a long-acting ß2-agonist and inhaled corticosteroid is appropriate.

Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.
Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.

The metered-dose inhaler is available in two strengths:

  • 25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
  • 25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)

Further information
View Sirdupla drug record 
Summary of Product Characteristics
Manufacturer: Mylan

Sirdupla can be used in patients over 18 years of age not adequately controlled with inhaled corticosteroids and an 'as needed' inhaled short-acting β2-agonist, and in those already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist.

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established.

Prescribers should note that only the AeroChamber Plus spacer device should be used with Sirdupla. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more